ExchangeDEX+

Buy Crypto Markets Spot FuturesGOLD Earn Event Center

Commodity Zero-Fee Gala

Cognition Therapeutics, Inc. (CGTX)

NASDAQ

$1,10

$-0,03

(-3,07%)

Cognition Therapeutics, Inc. (CGTX) Live Price Chart

Page last updated: 2026-02-12 00:57:00

Key Market Data

Market Cap	$97,10M
Open	$1,16
High	$13,80
Low	$0,22
Previous Close	$1,14
Price Change	$-0,03
Percentage Change	-3,07%
Volume	573K

Cognition Therapeutics, Inc. (CGTX) Stock Price Today

Cognition Therapeutics, Inc. (CGTX) is currently trading at $1,10 as of 2026-02-12 00:57:00, reflecting a -3,07% move ($-0,03) from the previous close.

In the short term, the stock has returned -2 307,69% over the past four weeks. Over the last 12 months, Cognition Therapeutics, Inc. has recorded a +88,26% price change, indicating a strong performance relative to the broader market.

Cognition Therapeutics, Inc. (CGTX) 7-Day Stock Price Changes

Over the past seven days, Cognition Therapeutics, Inc. has traded within a short-term range shaped by market sentiment in the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) sector. During this period, the stock moved from its previous closing price of $1,04 to the latest recorded price of $1,10, reflecting an intraday change of -3,07%. Daily movements highlight shifts in trading volume (572 549), investor positioning, and reactions to macroeconomic updates.

From a momentum standpoint, CGTX has delivered a -2 307,69% return over the past month and a +88,26% change in the last 12 months, indicating a strong trend relative to its broader sector peers.

How to Buy Cognition Therapeutics, Inc. (CGTX)

You can buy and trade CGTX on MEXC in three simple steps:

Step 1: Create and Verify Your MEXC Account

Sign up on MEXC and complete the required identity verification (KYC). This ensures full access to trading features and secure funding options.

Step 2: Deposit Funds Into Your Account

Choose your preferred payment method to add USDT or other supported assets to your MEXC wallet. Depositing crypto is the fastest way to get started.

Step 3: Search for CGTX and Execute Your Trade

Open the trading page, enter CGTX in the search bar, select the amount of CGTX you would like to purchase. Place a market order for instant execution or a limit order to buy at your target price.

What is Cognition Therapeutics, Inc. (CGTX)?

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Cognition Therapeutics, Inc. Information

Industry	BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Employees	25
Sector	BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Company Website	https://www.cogrx.com

Frequently Asked Questions (FAQ)

1.What is the current share price of Cognition Therapeutics, Inc.?

The latest trading price for Cognition Therapeutics, Inc. (Common Stock) is $ 1,10, compared with a previous closing price of $ 1,14. That means the stock has moved -3,07% so far today. Intraday price updates and recent trading activity for CGTX can be tracked on the live chart and quote section on this page.

2.Is Cognition Therapeutics, Inc. stock going up or down?

Looking at recent performances, CGTX has returned -2 307,69% over the past month, -26,17% over the last six months and +88,26% over the past year. These figures capture share-price changes only, not the impact of dividends. Together they describe strong price momentum for Cognition Therapeutics, Inc. stock, but keep in mind that past returns do not guarantee future results.

3.Where does CGTX currently sit relative to its 52-week high and low?

In the most recent 52-week period, Cognition Therapeutics, Inc. has traded between a low of $ 0,22 and a high of $ 3,83. This 52-week range helps show where today's share price sits relative to its recent highs and lows, and is often used by investors to judge stock volatility, potential support and resistance levels, and whether CGTX is currently nearer the top or the bottom of its one-year trading band.

4.How is Cognition Therapeutics, Inc. classified by sector and industry?

Cognition Therapeutics, Inc. is classified in the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) sector. In practice, this means Cognition Therapeutics, Inc. is grouped with other companies that serve similar end-markets and operate under comparable competitive and regulatory conditions. For investors, knowing CGTX’s sector helps with portfolio diversification, peer comparisons, and understanding how broader trends affecting the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) sector could influence Cognition Therapeutics, Inc.’s performance.

5.Where is Cognition Therapeutics, Inc. listed and how large is it by market value?

Cognition Therapeutics, Inc. is listed on the NASDAQ stock exchange in United States. Based on a market capitalization of $ 97,10M, the company is classified as a Small-cap stock. Market cap gives a quick sense of Cognition Therapeutics, Inc.'s size and importance in the equity market and is often used by investors and index providers when constructing portfolios or benchmarks.

6.What does CGTX's EPS tell investors about its profitability?

Trailing-twelve-month EPS of $ -0,32 summarises how much profit Cognition Therapeutics, Inc. has generated per share over the last year. Rising EPS over time can signal improving profitability or effective share repurchases, while flat or declining EPS may point to slower growth or margin pressure. EPS is a key input into valuation metrics such as P/E and is often monitored closely around earnings announcements.

7.How can I track Cognition Therapeutics, Inc.'s financial performance over time?

To follow Cognition Therapeutics, Inc.'s financial performance, investors typically review its quarterly and annual reports, which include detailed income statements, balance sheets and cash-flow statements. Combining these filings with key market data shown on this page—such as share price trends, P/E and dividend yield—provides a more complete view of how CGTX is performing and how the market is responding.

8.When is Cognition Therapeutics, Inc. expected to report earnings?

Cognition Therapeutics, Inc.'s next scheduled earnings release is currently expected on -- (the date may be updated by the company). Earnings announcements often act as important catalysts for CGTX, as they provide updated information on revenue, profitability and management's outlook.

9.What usually comes out in Cognition Therapeutics, Inc.'s earnings reports?

Cognition Therapeutics, Inc.'s earnings reports typically include headline figures such as revenue, net income and EPS, along with commentary on segment performance, margins, cash flow and guidance for future periods. Investors compare these results with market expectations and prior periods to assess whether CGTX is meeting, beating or missing expectations.

10.How can I stay informed about Cognition Therapeutics, Inc.'s results and guidance?

You can stay up to date on Cognition Therapeutics, Inc. by reviewing its quarterly earnings releases, listening to or reading transcripts of earnings calls, and following company news and filings. Pairing this fundamental information with the price and return data for CGTX on this page helps you see how new information is being reflected in the stock.

11.Does Cognition Therapeutics, Inc. pay a regular cash dividend to its shareholders?

Cognition Therapeutics, Inc. Non-paying. Based on the latest information, the stock has an indicated annual cash dividend of -- per share and a current dividend yield of 0 at the recent share price. Dividends are typically paid --, although the board can change the dividend policy at any time. Income-focused investors often monitor CGTX's dividend level, payment frequency and any announcements about future dividends when assessing the stock's appeal as a dividend-paying investment.

12.What are the current dividend yield and dividend payout ratio for CGTX?

Based on the latest earnings data, CGTX has a dividend yield of 0 and a dividend payout ratio of 0. The dividend yield shows how much cash return an investor receives from dividends each year relative to the current share price, helping assess whether Cognition Therapeutics, Inc. is an attractive income stock. The dividend payout ratio measures what percentage of earnings Cognition Therapeutics, Inc. distributes to shareholders as dividends versus how much it retains to reinvest in the business, which is an important indicator of dividend sustainability and room for future dividend growth.

13.What kind of business is Cognition Therapeutics, Inc.?

Cognition Therapeutics, Inc. is a publicly traded company in the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry within the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) sector. It generates revenue from products and services related to this core business area, and investors can find a detailed description of its operations, strategy and geographic exposure in the company's annual report and other regulatory filings.

14.How is CGTX valued in terms of P/E ratio and EPS?

Cognition Therapeutics, Inc. currently trades at a price-to-earnings (P/E) ratio of --, based on trailing-twelve-month earnings per share (EPS) of $ -0,32. P/E is calculated by dividing the share price by EPS and shows how much investors are paying today for each unit of Cognition Therapeutics, Inc.'s earnings. Comparing CGTX's P/E and EPS to those of other BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) companies can help investors judge whether its valuation looks rich or attractive.

Explore More US Stocks

Stocks in the Same Sector

Browse other US stocks in the same sector as Cognition Therapeutics, Inc.

The Walt Disney Company

DIS

Largest Market Cap

See US stocks with the highest market capitalization

Berkshire Hathaway Inc.

BRK.A

Alphabet Inc.

GOOG

Most Actively Traded

Discover today's most actively traded US stocks

American Superconductor Corp.

AMSC

Charter Comm Inc Del CL A New

CHTR

Core Scientific, Inc.

CORZ

Crocs, Inc.

CROX

FACT II Acquisition Corp.

FACT

Top Gainers

Browse today's leading gainers in the US stock market

Greenlane Holdings, Inc.

Top 5 Cryptocurrencies

Explore the cryptocurrencies with the highest market capitalization

BTC

ETH

SOL

Disclaimer

The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.

CGTX-to-USD Calculator

Amount

CGTX

USD

1 CGTX = 1,1 USD